Myome
MyOme, founded in 2017, is a clinical genomic medicine company that empowers individuals and healthcare providers with actionable genomic insights through whole genome sequencing and advanced bioinformatics. Their platform delivers comprehensive, clinically relevant reports from a single patient sample, enabling personalized lifestyle, prevention, and treatment decisions. MyOme offers proactive health tests such as Single-Gene Risk, Medication Response, and Integrated Polygenic Risk Scores (iPRS), as well as diagnostic tests for rare diseases. Their proprietary iPRS technology is validated across diverse ancestries, ensuring precise risk assessments. The company prioritizes data security and patient ownership of genomic data, integrating seamlessly into clinical workflows to reduce provider burden. MyOme is positioned as a leader in personalized genomic healthcare with a strong scientific foundation and collaborations with clinical labs and research institutions.
Myome
MyOme, founded in 2017, is a clinical genomic medicine company that empowers individuals and healthcare providers with actionable genomic insights through whole genome sequencing and advanced bioinformatics. Their platform delivers comprehensive, clinically relevant reports from a single patient sample, enabling personalized lifestyle, prevention, and treatment decisions. MyOme offers proactive health tests such as Single-Gene Risk, Medication Response, and Integrated Polygenic Risk Scores (iPRS), as well as diagnostic tests for rare diseases. Their proprietary iPRS technology is validated across diverse ancestries, ensuring precise risk assessments. The company prioritizes data security and patient ownership of genomic data, integrating seamlessly into clinical workflows to reduce provider burden. MyOme is positioned as a leader in personalized genomic healthcare with a strong scientific foundation and collaborations with clinical labs and research institutions.
TL;DR
Founded: 2017
Headquarters: Menlo Park / Palo Alto, California
Product: Clinical whole-genome analysis with integrated polygenic risk scores (iPRS)
Regulatory lab: Operates a CLIA-certified, CAP-accredited laboratory
Recent financing: Series B announced Jun 21, 2022
Company Overview
Problem Domain
Personalized genomic healthcare: inherited disease risk assessment, preventive screening, and diagnostic genetic testing.
Founded
2017
Industry
Genomics / Clinical diagnostics
Tech Stack
Funding Track Record
23000000.00
Oversubscribed round; reported to add investors including SoftBank Corp. and Natera; brought reported total funding to over $36M per company announcement.
Investor Signal
“Includes strategic and prominent healthcare investors such as Healthcare Venture Partners, SoftBank Corp., Natera, Sequoia Capital, Foresite Capital, and Founders Fund”